Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24...

Descripción completa

Detalles Bibliográficos
Autores principales: Connor, Bradley A, Couto-Rodriguez, Mara, Barrows, Joseph E, Gardner, Morgan, Rogova, Marina, O'Hara, Niamh B., Nagy-Szakal, Dorottya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276551/
https://www.ncbi.nlm.nih.gov/pubmed/34271202
http://dx.doi.org/10.1016/j.ijid.2021.07.029
_version_ 1783721924764893184
author Connor, Bradley A
Couto-Rodriguez, Mara
Barrows, Joseph E
Gardner, Morgan
Rogova, Marina
O'Hara, Niamh B.
Nagy-Szakal, Dorottya
author_facet Connor, Bradley A
Couto-Rodriguez, Mara
Barrows, Joseph E
Gardner, Morgan
Rogova, Marina
O'Hara, Niamh B.
Nagy-Szakal, Dorottya
author_sort Connor, Bradley A
collection PubMed
description We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.
format Online
Article
Text
id pubmed-8276551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-82765512021-07-14 Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case Connor, Bradley A Couto-Rodriguez, Mara Barrows, Joseph E Gardner, Morgan Rogova, Marina O'Hara, Niamh B. Nagy-Szakal, Dorottya Int J Infect Dis Case Report We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-13 /pmc/articles/PMC8276551/ /pubmed/34271202 http://dx.doi.org/10.1016/j.ijid.2021.07.029 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Connor, Bradley A
Couto-Rodriguez, Mara
Barrows, Joseph E
Gardner, Morgan
Rogova, Marina
O'Hara, Niamh B.
Nagy-Szakal, Dorottya
Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
title Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
title_full Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
title_fullStr Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
title_full_unstemmed Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
title_short Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
title_sort monoclonal antibody therapy in a vaccine breakthrough sars-cov-2 hospitalized delta (b.1.617.2) variant case
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276551/
https://www.ncbi.nlm.nih.gov/pubmed/34271202
http://dx.doi.org/10.1016/j.ijid.2021.07.029
work_keys_str_mv AT connorbradleya monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase
AT coutorodriguezmara monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase
AT barrowsjosephe monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase
AT gardnermorgan monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase
AT rogovamarina monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase
AT oharaniamhb monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase
AT nagyszakaldorottya monoclonalantibodytherapyinavaccinebreakthroughsarscov2hospitalizeddeltab16172variantcase

Ejemplares similares